-
公开(公告)号：US20160108050A1
公开(公告)日：2016-04-21
申请号：US14976476
申请日：2015-12-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer lnghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann , Yong Zhang , Libing Chen , Bin Chen , John S. Tokarski , Ashvinikumar V. Gavai
IPC: C07D487/04 , C07F9/6561 , C07F7/18 , C07D519/00
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US09273057B2
公开(公告)日：2016-03-01
申请号：US14414152
申请日：2013-07-12
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann , Yong Zhang , Libing Chen , Bin Chen , John S. Tokarski , Ashvinikumar V. Gavai
IPC: C07D487/04 , C07D487/08 , C07D487/10 , C07D471/10 , C07D498/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61P19/02 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07F9/6521 , C07D519/00 , C07F9/6561 , C07F7/18
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US20160022619A1
公开(公告)日：2016-01-28
申请号：US14776035
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Bin Chen , Libing Chen , Steven P. Seitz , Amy C. Hart , Jay A. Markwalder
IPC: A61K31/196 , A61K31/505 , A61K31/44 , A61K31/41 , A61K31/4245 , A61K31/42 , A61K31/36 , A61K31/27 , A61K31/216 , A61K31/18 , C07D239/42 , C07D241/42 , C07D213/84 , C07D213/75 , C07D271/12 , C07D261/14 , C07D257/04 , C07D317/66 , C07C271/28 , C07C69/743 , C07C275/42 , C07C311/47 , A61K45/06 , C07C233/55 , A61N5/10 , A61K31/498
CPC classification number: A61K31/196 , A61K31/18 , A61K31/216 , A61K31/27 , A61K31/36 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/44 , A61K31/498 , A61K31/505 , A61K45/06 , A61N5/10 , C07B2200/07 , C07C69/743 , C07C233/55 , C07C235/38 , C07C255/44 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/47 , C07C311/51 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/02 , C07C2602/08 , C07C2602/14 , C07C2602/42 , C07D213/56 , C07D213/75 , C07D213/84 , C07D239/42 , C07D241/42 , C07D257/04 , C07D261/08 , C07D261/14 , C07D271/12 , C07D317/66 , Y02A50/411 , Y02A50/414
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
Abstract translation: 公开了调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病如癌症，病毒感染和/或炎症性疾病的方法，其利用 发明。
-
公开(公告)号：US09656963B2
公开(公告)日：2017-05-23
申请号：US14442624
申请日：2013-11-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Andres S. Hernandez , Bruce A. Ellsworth , William R. Ewing , Bin Chen
IPC: C07D231/06 , C07D403/12 , C07D231/08 , C07D401/10 , C07D403/04 , C07D401/04 , C07D401/12 , C07D403/10 , C07D413/04 , A61K45/06 , A61K31/4155 , A61K31/415 , A61K31/506 , A61K31/497 , A61K31/422 , A61K31/4439
CPC classification number: C07D231/06 , A61K31/415 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K45/06 , C07D231/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D413/04 , A61K2300/00
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
-
Patent Agency Ranking
公开(公告)号：US20160060237A1
公开(公告)日：2016-03-03
申请号：US14775976
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Bin Chen , Libing Chen , Weifang Shan
IPC: C07D305/06 , A61K31/196 , A61K31/337 , C07D261/14 , A61K31/42 , A61K45/06 , A61K31/41 , C07D241/42 , A61K31/498 , C07D239/42 , A61K31/505 , C07C275/42 , C07D255/02
CPC classification number: C07D305/06 , A61K31/196 , A61K31/337 , A61K31/41 , A61K31/42 , A61K31/498 , A61K31/505 , A61K45/06 , C07C275/42 , C07C2101/14 , C07C2601/14 , C07D239/42 , C07D241/42 , C07D255/02 , C07D261/14
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
Abstract translation: 公开了调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病的方法，例如癌症，病毒感染和/或自身免疫疾病，其利用 发明。 式（I）。
-
公开(公告)号：US20150210697A1
公开(公告)日：2015-07-30
申请号：US14414152
申请日：2013-07-12
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer Inghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann , Yong Zhang , Libing Chen , Bin Chen , John S. Tokarski , Ashvinikumar V. Gavai
IPC: C07D487/04 , C07F7/18 , C07D487/10 , C07D487/08 , C07D471/10
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US09675571B2
公开(公告)日：2017-06-13
申请号：US14776035
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Bin Chen , Libing Chen , Steven P. Seitz , Amy C. Hart , Jay A. Markwalder
IPC: A61K31/135 , A61K31/196 , C07C255/44 , C07C255/57 , C07D213/84 , C07C275/42 , C07D317/66 , C07C311/51 , C07D239/42 , C07D241/42 , C07D257/04 , C07D261/08 , C07C233/55 , C07D261/14 , C07C235/38 , C07D271/12 , C07D213/56 , A61K31/18 , A61K31/216 , A61K31/27 , A61K31/36 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/44 , A61K31/498 , A61K31/505 , A61K45/06 , A61N5/10 , C07C69/743 , C07C271/28 , C07C311/47 , C07D213/75
CPC classification number: A61K31/196 , A61K31/18 , A61K31/216 , A61K31/27 , A61K31/36 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/44 , A61K31/498 , A61K31/505 , A61K45/06 , A61N5/10 , C07B2200/07 , C07C69/743 , C07C233/55 , C07C235/38 , C07C255/44 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/47 , C07C311/51 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/02 , C07C2602/08 , C07C2602/14 , C07C2602/42 , C07D213/56 , C07D213/75 , C07D213/84 , C07D239/42 , C07D241/42 , C07D257/04 , C07D261/08 , C07D261/14 , C07D271/12 , C07D317/66 , Y02A50/411 , Y02A50/414
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US09624188B2
公开(公告)日：2017-04-18
申请号：US14775976
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Bin Chen , Libing Chen , Weifang Shan
IPC: C07D305/06 , A61K31/196 , C07C275/42 , C07D239/42 , C07D241/42 , C07D255/02 , A61K31/337 , A61K31/41 , A61K31/42 , A61K31/498 , A61K31/505 , A61K45/06 , C07D261/14
CPC classification number: C07D305/06 , A61K31/196 , A61K31/337 , A61K31/41 , A61K31/42 , A61K31/498 , A61K31/505 , A61K45/06 , C07C275/42 , C07C2101/14 , C07C2601/14 , C07D239/42 , C07D241/42 , C07D255/02 , C07D261/14
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
-
公开(公告)号：US20160280659A1
公开(公告)日：2016-09-29
申请号：US14442624
申请日：2013-11-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Andres S. Hernandez , Bruce A. Ellsworth , William R. Ewing , Bin Chen
IPC: C07D231/06 , C07D231/08 , C07D403/04 , A61K31/4155 , C07D413/04 , A61K31/422 , C07D401/12 , A61K31/4439 , C07D403/10 , A61K31/506 , C07D401/04 , C07D403/12 , C07D401/10 , A61K31/497 , A61K45/06 , A61K31/415
CPC classification number: C07D231/06 , A61K31/415 , A61K31/4155 , A61K31/422 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K45/06 , C07D231/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D413/04 , A61K2300/00
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的GPR40G蛋白偶联受体调节剂。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.037 seconds)
